secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-10-20T23:59:59+00:00
Accession:  0001493152-25-018634
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir signs binding LOI to acquire TELI, consolidating worldwide rights to Telomir-1
--------------------------------------------------------------------------------

- Acquires all TELI shares via stock-for-stock exchange; exchange ratio based on third-party valuation.
- Certain TELI shareholders to contribute $5M cash: $1M at closing, $2M on FDA IND acceptance, $2M on Phase 1/2 start.
- Transaction consolidates global IP rights to Telomir-1, an oral epigenetic therapy for cancer and aging.
- No TELI leadership retained post-closing; TELI shareholders subject to six-month lock-up.
- Closing subject to due diligence, board/stockholder approvals, regulatory clearances within 90 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225018634/0001493152-25-018634-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225018634/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-018634

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer